Loading...
Please wait, while we are loading the content...
Similar Documents
Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—Which TKI is the safest?
| Content Provider | Scilit |
|---|---|
| Author | Eşkazan, Ahmet Emre |
| Copyright Year | 2019 |
| Description | Journal: British journal of clinical pharmacology |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783590/pdf |
| Ending Page | 2243 |
| Page Count | 3 |
| Starting Page | 2241 |
| e-ISSN | 13652125 |
| DOI | 10.1111/bcp.14092 |
| Journal | British journal of clinical pharmacology |
| Issue Number | 10 |
| Volume Number | 85 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2019-10-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: British journal of clinical pharmacology Health Policy and Services Adverse Event Chronic Myeloid Leukaemia Haematologic Toxicity Tyrosine Kinase Inhibitor |
| Content Type | Text |